Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
196 hedge funds and large institutions have $2.35B invested in Global Blood Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 86 increasing their positions, 48 reducing their positions, and 23 closing their positions.
106% more call options, than puts
Call options by funds: $180M | Put options by funds: $87.2M
91% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 23
79% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 48
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11% more funds holding
Funds holding: 176 → 196 (+20)
3% less capital invested
Capital invested by funds: $2.41B → $2.35B (-$61.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$54M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$45.5M |
| 3 |
BlackRock
New York
|
+$40.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$20.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$48.5M |
| 2 |
O
OrbiMed
New York
|
-$46.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$24.5M |
| 5 |
RI
RTW Investments
New York
|
-$22.1M |
GBT Hedge Fund Activity: Q2 2018 in Review
196 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2018, worth a combined $2.35B — down 2.6% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new GBT positions and 23 closed out — a net gain of 21 holders — while 86 added to existing stakes and 48 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $54M. The largest seller was Avoro Capital Advisors, cutting an estimated $48.5M.
- 196 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2018, up from 176 in Q1 2018.
- Funds reported $2.35B of Global Blood Therapeutics, Inc. stock for Q2 2018, down 2.6% quarter-over-quarter.
- 44 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2018 and 23 closed out, a net change of +21 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2018 was Farallon Capital Management, an estimated $54M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2018 was Avoro Capital Advisors, an estimated $48.5M sold.
Based on aggregated 13F filings for Q2 2018.